Case Report: Osimertinib-induced acute interstitial lung disease
Osimertinib is a third-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively targets EGFR-TKI-sensitive mutations, thereby inhibiting tumor cell proliferation, migration, and invasion. Herein, we present a case of osimertinib-induced interstit...
Saved in:
| Main Authors: | Zhiwu Lin, Liang Wu, Yang Yu, Jiudong Jiang, Yanchun Yang, Guibao Xiao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1608733/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
First‐Line Osimertinib for EGFR‐Mutated Squamous Cell Lung Carcinoma: A Case Report
by: Yugo Matsumura, et al.
Published: (2025-07-01) -
HDAC5, an early osimertinib-responsive gene, is a novel therapeutic target for the drug resistance in EGFR-mutant lung adenocarcinoma cells
by: Hanbing Lyu, et al.
Published: (2025-06-01) -
Safety and efficacy of the combination of selpercatinib with osimertinib in NSCLC: a case report and review of the literature
by: Blerina Resuli, et al.
Published: (2025-05-01) -
CircSPINT2 confers sensitivity to osimertinib via hsa-miR-1296-3p/RBP1 axis and inhibits NSCLC progression
by: Nalini Devi Verusingam, et al.
Published: (2025-09-01) -
Co-occurrence of interstitial lung disease and pulmonary embolism as adverse events of adjuvant osimertinib treatment for EGFR mutant non-small cell lung cancer: a case report
by: Kenta Manabe, et al.
Published: (2025-07-01)